Ever wonder where biotech start-ups get their big, bold ideas? Biotech innovation often starts in academic labs—usually funded partially by the National Institutes of Health (NIH)—where scientists are busy decoding the causes of disease. But turning those eureka moments into life-saving treatments? That’s where start-ups step in.

How It Works

• NIH and Funding: The NIH doles out over $48 billion annually to fund academic research on everything from cancer-killing small molecules to next-generation gene therapies. Scientists in universities and research institutes apply for NIH grants to fund their research.
• Publish or Perish: Academic scientists publish their research findings in high-impact scientific journals like Nature, Science, and Cell. “Publish or Perish” in biotech (and academia in general) refers to the intense pressure on scientists to constantly publish research papers to stay relevant, secure funding, and advance their careers.
• Licensing the Next Breakthroughs: When groundbreaking discoveries hit journals, the papers aren’t just for prestige; it’s often the first step toward commercializing. Entrepreneurs, start-ups, and established pharma companies comb through them, looking for the next breakthrough they can license and develop into a blockbuster drug. The university tech transfer office steps in, licensing the intellectual property (IP) to interested parties.
• License or Launch: Scientists can either license their technology or launch their own start-ups (because who doesn’t love a little entrepreneurial adrenaline?). Either way, the long road toward commercialization begins.
• VCs Enter the Chat: Venture capitalists (VCs) are always on the hunt for the next CRISPR, RNA therapeutic, or AI-powered drug discovery platform. They fund start-ups, providing the cash to turn discovery into a clinical-stage company.
• SBIR and STTR: No VC? No problem. The NIH fuels biotech start-ups with SBIR and STTR grants to turn cutting-edge research into real-world treatments.

Commercialization Readiness

Biotech Primer, BIO’s affiliate training partner, will teach the Commercialization Readiness course at BIO2025. Attending BIO2025? Check the box to attend our course during registration. Not attending BIO2025? You can still join us! Click above and fill out your information. Use coupon code STAND25 during checkout, and you will be all set. See you in Boston!

Why It Matters

Without NIH-funded research, the biotech industry wouldn’t exist. Every major breakthrough—CRISPR, mRNA vaccines, CAR-T therapies—started with federal government-funded science. And those peer-reviewed publications? They’re the breadcrumbs that lead to life-saving treatments.

MVP

Your tax dollars fuel the earliest stages of biotech innovation. The NIH funds academic research, academia publishes breakthroughs in scientific journals, and start-ups license the tech from universities to bring cutting-edge treatments to the world. And when those start-ups succeed? Universities and the scientists who made the initial discovery get a slice, investors cash in, and—most importantly—you, the patient, benefit. If biotech is a team sport, NIH is the MVP.

Your Biotech Start-Up Blueprint

Join Biotech Primer on February 12, 2025, for a free, live Biotech Start-Up Formation and Funding course! Learn the ins and outs from a serial entrepreneur, Al Hawkins, who has been there and done that! Use coupon code BIOFUNDING to attend for free. Preregistration is required. Register by February 11 and join us for 60 minutes of start-up insights.